MYC and lymphoma: While MYC expression is dysregulated in a wide variety of cancers, it's oncogenic role has most thoroughly been studied in vivo in the context of transgenic models of aggressive breast, liver, lung, prostate, and kidney cancers, as well as neuroblastoma and lymphoma (see references below; Figure 1 and Table 1).